Generic Temovate 0.05%

Introduction

Temovate .05 % is a high‑potency topical corticosteroid indicated for a range of inflammatory skin disorders. The product contains the synthetic glucocorticoid clobetasol propionate, a molecule that reduces redness, swelling and itching by suppressing local immune responses. In the United Kingdom the medication is classified within the Skin Care group and is marketed by several licensed manufacturers. Its primary clinical use is for short‑term treatment of severe eczema, psoriasis, and other dermatological conditions that have not responded to milder steroids.

What is a Temovate .05 %?

Temovate .05 % is a cream, ointment or lotion formulation that delivers .05 % (w/w) clobetasol propionate to the skin. The product belongs to the class of ultra‑potent (Class I) topical corticosteroids. It was developed to provide rapid anti‑inflammatory relief for conditions where lower‑strength steroids are insufficient. Several manufacturers distribute the preparation in the UK, all of which must meet the standards set by the Medicines and Healthcare products Regulatory Agency (MHRA).

Generic reference: Temovate .05 % is the generic version of the original brand Dermovate, which also contains clobetasol propionate. Our online pharmacy provides this generic alternative as a cost‑effective treatment option.

How Temovate .05 % Works

Clobetasol propionate binds to intracellular glucocorticoid receptors in keratinocytes and immune cells of the epidermis and dermis. The drug‑receptor complex translocates to the nucleus, where it modulates gene transcription. Key actions include:

• Inhibition of pro‑inflammatory cytokine production (e.g., interleukin‑1, tumour necrosis factor‑α).
• Suppression of leukocyte migration and reduced capillary permeability, which diminishes oedema and erythema.
• Stimulation of anti‑inflammatory proteins such as annexin‑1, leading to rapid symptom relief.

Because clobetasol’s anti‑inflammatory effect is concentration‑dependent, the .05 % formulation achieves a clinical response within 24–48 hours for most patients. The drug is largely metabolised locally; systemic absorption is minimal when applied to intact skin over limited body surface area.

Conditions Treated with Temovate .05 %

• Plaque psoriasis – especially thick, resistant plaques on the scalp, elbows or knees.
• Atopic dermatitis (eczema) – severe flare‑ups that have not improved with lower‑strength steroids.
• Seborrhoeic dermatitis – refractory cases involving the scalp or face.
• Discoid lupus erythematosus – localized lesions requiring potent anti‑inflammatory control.
• Lichen planus – hypertrophic variants that cause significant discomfort.

In the UK, psoriasis affects approximately 2 % of the adult population, making it a common indication for high‑potency topical therapy. Severe eczema also impacts several hundred thousand adults, often necessitating intensified treatment regimens such as Temovate .05 %.

Who is Temovate .05 % For?

Suitable patient populations

• Adults with moderate‑to‑severe inflammatory dermatoses that have not responded adequately to weaker corticosteroids (e.g., betamethasone .05 %).
• Individuals requiring short‑term, localized control of plaques or oozing lesions on limited skin areas (typically ≤ 10 % of body surface).
• Patients who can apply the medication under medical supervision, allowing monitoring for potential adverse effects.

Contra‑indications / situations where use is not appropriate

• Children under 12 years unless explicitly prescribed, because the risk of systemic absorption is higher.
• Extensive skin damage, such as open wounds, burns, or active viral skin infections (e.g., herpes simplex).
• Chronic skin conditions requiring long‑term steroid exposure; alternative therapies (e.g., calcineurin inhibitors) should be‑used.

Risks, Side Effects, and Interactions

Common

• Burning, stinging or itching at the application site.
• Mild skin atrophy (thinning) with prolonged use.
• Folliculitis or acne‑like eruptions.

Rare

• Telangiectasia (visible small blood vessels).
• Hypopigmentation or hyperpigmentation of the treated area.
• Perioral dermatitis when applied near the mouth.

Serious

• Systemic corticosteroid effects (e.g., adrenal suppression, hyperglycaemia) if large surface areas are treated or occlusive dressings are used.
• Severe allergic reaction (angio‑edema, anaphylaxis) – extremely uncommon but requires immediate medical attention.
• Secondary skin infections (bacterial, fungal) due to local immunosuppression.

Drug‑Drug Interactions

• Systemic immunosuppressants (e.g., ciclosporin) may increase the risk of infection when combined with high‑potency topical steroids.
• Antifungal agents such as ketoconazole may potentiate local steroid activity; concurrent use should be reviewed by a clinician.
• Enzyme – topical agents containing other potent steroids should not be layered unless directed, to avoid cumulative dose escalation.

Patients should always inform their healthcare provider of all prescribed, over‑the‑counter and herbal products they are using.

Practical Use: Dosing, Missed Dose, Overdose

• Standard dosing: Apply a thin film of Temovate .05 % to the affected area once daily for up to 2 weeks, or as directed by a prescriber. Do not exceed the recommended surface area (generally ≤ 10 % of total body surface).
• Missed dose: If a dose is forgotten, apply it as soon as remembered unless it is close to the time of the next scheduled application; in that case, skip the missed dose and continue with the regular schedule. Do not double‑dose.
• Overdose: Excessive application (large areas, multiple daily doses) may lead to systemic absorption. Symptoms such as unexplained weight gain, facial swelling, or severe skin thinning require urgent medical review.
• Precautions:
  • Avoid covering the treated skin with occlusive dressings unless instructed, as this can increase absorption.
  • Do not use on the face, groin or armpits unless specifically advised, because these sites are more prone to atrophy.
  • Alcohol consumption does not directly affect topical absorption, but patients with diabetes should monitor blood glucose if extensive skin areas are treated.

Buying Temovate .05 % from Our Online Pharmacy

Temovate .05 % can be purchased from our online pharmacy in the UK, offering a discreet, cost‑effective avenue for patients who experience limited availability through local high‑street pharmacies.

• Affordable pricing – We source the medication at near‑manufacturer cost, passing savings directly to the patient.
• Verified quality – All products are supplied by MHRA‑approved overseas licensed pharmacies and undergo stringent quality checks before dispatch.
• Guaranteed delivery – Options include 7‑day express service for urgent needs and ~3‑week regular airmail for non‑urgent orders. Packages are shipped in discreet, tamper‑evident containers.
• Online‑only access – Our pharmacy broker service collaborates with international suppliers, enabling patients to obtain medications that may not be stocked locally while maintaining full compliance with UK import regulations.
• Privacy‑focused – We respect for patient confidentiality is built into every step, from order processing to delivery.

Patients seeking a reliable source for Temovate .05 % should consider our platform as a safe alternative when traditional channels are unavailable or financially prohibitive.

FAQ

• Is Temovate .05 % available in both cream and ointment formulations?
  Yes, the medication is marketed in several topical bases, most commonly as a cream, ointment and lotion. The choice of vehicle depends on the affected skin area and patient preference; ointments provide a more occlusive barrier, while creams are less greasy and easier to spread.

• What should be done if the tube of Temovate .05 % becomes empty before the treatment course ends?
  Do not resume treatment with a new tube until you have consulted a qualified healthcare professional. Restarting without guidance may lead to inappropriate dosing or unnecessary prolonged exposure.

• Can Temovate .05 % be stored in a bathroom cabinet?
  It should be kept at room temperature (15–25 °C) away from excess moisture and direct sunlight. Bathrooms can be humid, which may degrade the formulation over time, so a dry cupboard‑type storage is preferable.

• Does the medication have any known incompatibilities with cosmetic products?
  Applying heavy moisturisers or makeup over a freshly applied dose can dilute the steroid and reduce its effectiveness. It is advisable to allow the medication to absorb for at least 15 minutes before applying other topicals.

• Are there any specific travel considerations for Temovate .05 %?
  When travelling internationally, keep the product in its original packaging with a clear label to avoid customs issues. If the journey exceeds six months, ensure the medication has not passed its expiry date before use.

• How does clobetasol propionate differ from older steroids such as hydrocortisone?
  Clobetasol is classified as an ultra‑potent (Class I) corticosteroid, whereas hydrocortisone is a mild (Class VII) agent. The higher receptor affinity of clobetasol results in a stronger anti‑inflammatory effect, but also a higher risk of adverse skin changes if misused.

• What are the key differences between UK‑registered and EU‑registered formulations of Temovate .05 %?
  Both meet stringent quality standards, yet minor variations may exist in inactive ingredients (e.g., emulsifiers or preservatives). These excipients can affect skin tolerability for individuals with sensitivities; patients should review the ingredient list if they have known allergies.

• Can the use of Temovate .05 % affect drug testing results?
  Topical clobetasol is unlikely to produce detectable systemic levels that would influence standard drug screens. However, extraordinarily high or extensive application could theoretically lead to trace systemic absorption, though this scenario is rare.

• Is there any evidence that clobetasol propionate can cause skin cancer with long‑term use?
  Current clinical data do not demonstrate a direct carcinogenic effect of topical clobetasol when used as recommended. Nevertheless, prolonged use over large body areas may increase the risk of skin atrophy, which can complicate the early detection of skin malignancies. Regular dermatological review is advised for chronic users.

• What packaging sizes are typically offered for Temovate .05 %?
  Commercially, the medication is supplied in tubes ranging from 15 g to 30 g for cream or ointment forms. Some suppliers also provide 45 g tubes for extended treatment courses.

Glossary

Glucocorticoid receptor

A protein inside cells that binds corticosteroids, initiating a cascade that alters gene expression and reduces inflammation.

Skin atrophy

Thinning of the epidermis and dermis that can occur after prolonged exposure to potent topical steroids, leading to increased fragility.

Systemic absorption

The process by which a drug applied to the skin enters the bloodstream and may affect other organ systems beyond the site of application.

Occlusive dressing

A moisture‑tight covering (e.g., plastic wrap) applied over a topical medication to enhance penetration; it can significantly increase systemic exposure.

⚠️ Disclaimer

The information provided about Temovate .05 % is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Temovate .05 % for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.